Enterprise Value
12.0M
Cash
37.27M
Avg Qtr Burn
-6.866M
Short % of Float
8.32%
Insider Ownership
29.70%
Institutional Own.
15.31%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Plinabulin (Tubulin selective immunomodulating microtubule-binding agent) Details Non-small cell lung carcinoma, Lung cancer | NDA FDA meeting | |
Plinabulin (Tubulin selective immunomodulating microtubule-binding agent) Details Chemotherapy-induced neutropenia, Cancer | NDA FDA meeting |